Detalhe da pesquisa
1.
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8. 7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
Eur. heart j;
42(31): 2995-3007, Aug. 2021. graf, tab
Artigo
em Inglês
| CONASS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1292869
2.
Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin
Gastroenterology;
157(3): 682-691, ago., 30 2019. ilus, tab
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1015771
3.
Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial
Gastroenterology;
157(2): 403-412, Aug., 2019. tab, graf
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1022748
4.
Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE
Eur Heart J Cardiovasc Pharmacother;
4(2): 75-81, Apr. 2018. tab, graf
Artigo
em Inglês
| SES-SP, CONASS, SESSP-IDPCPROD, SES-SP | ID: biblio-1223607
5.
Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial
Can J Cardiol;
33(8): 1027-1035, 2017. ilus, tab
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1061784
6.
Apixaban in patients with atrial fibrillation
N. Engl. j. med;
364(9): 806-817, 2011. ilus, tab
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1064869